title: Molecular Property Design: Does Everyone Get It?
abstract: The principles of molecular property optimization in drug design have been understood for decades, yet much drug discovery activity today is conducted at the periphery of historical druglike property space. Lead optimization trajectories aimed at reducing physicochemical risk, assisted by ligand efficiency metrics, could help to reduce clinical attrition rates.
authors.affiliation: Paul Leeson Consulting Ltd. , The Malt House, Main Street, Congerstone, Nuneaton, Warwickshire CV13 6LZ, U.K.
authors.forename: Paul D
authors.initials: PD
authors.lastname: Leeson
authors.affiliation: Medicines Research Centre, GlaxoSmithKline , Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, U.K.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Young